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1. Abstract 
Graft-versus-host disease (GVHD) is a potentially severe complication that may develop in different 
tissues including the eye after allogenic hematopoietic stem cell transplantation (HSCT). 
The purpose of this research project was to evaluate ocular surface parameters of patients undergoing 
HSCT before and after transplantation, and to correlate them with clinical and HSCT features.  
Data from the charts of ninety-three patients affected by hematological malignancies undergoing HSCT 
were collected. Values of Ocular Surface Disease Index, Schirmer Test type I, Tear Film Break-up 
Time, ocular surface staining and Meibomian Gland Dysfunction score obtained before HSCT and 3-6 
months after were retrieved from charts. Diagnosis and staging of Dry Eye disease (DED) was 
performed according to Dry Eye WorkShop criteria. GVHD was classified according to the National 
Institutes of Health (NIH) 2015 Criteria. Odds ratios for DED onset after HSCT were estimated for 
demographic, ocular, hematological and HSCT features.  
Dry eye disease was diagnosed before HSCT in 50 (53%) of the patients, mostly of hyper-evaporative 
profile. After HSCT all ocular parameters significantly worsened with no change in DE profile. A 51% 
of incident cases (22 on the 43 non-DE subjects) were reported. Increasing recipient age and female 
sex, higher CD34+ cells infused, donor-recipient sex mismatch (males receiving from females), related 
donors, and peripheral blood cells as stem cell source were associated with a significant higher 
incidence of DED after HSCT. Systemic chronic GVHD was diagnosed in 42% while ocular GVHD in 
35.5% of the patients, which decreased to 12% when taking into account only incident cases. 
In conclusion, a high DE prevalence was shown already before HSCT. Therefore, an ocular surface 
assessment should be recommended already before HSCT for early DED diagnosis and treatment. This 
new protocol also could influence the real prevalence of ocular GVHD after HSCT and its severity. 
Key words: Ocular Graft versus-host disease; Dry eye disease; Hematopoietic stem cell 
transplantation.  
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2. INTRODUCTION 
 
2.1) The ocular surface 
The ocular surface system consists of the cornea, conjunctiva, lachrymal and meibomian glands, 
nasolacrimal duct, and their associated tear and connective tissue matrices, as well as the eyelids and 
eyelashes, all integrated by continuous epithelia and interconnected nervous, endocrine, immune, and 
vascular systems (Figure 1).1 This functional unit protects the eye from the external environment and 
provides for an optimal refractive surface of the cornea through the production of an efficient tear 
film.2 
The cornea has the highest dioptric power of the optical complex; it needs to be avascular in order to 
be transparent and receive its nutrients through diffusion from the tear film and aqueous humor. The 
cornea is one of the body structures most densely innervated and the innervations comes from axons of 
the sympathetic ganglion and trigeminal ganglion. The epithelium is the external layer, underneath is 
Bowman’s layer, stroma, the recently recognized Dua ́s layer, Descemet’s membrane and at the most 
inner level the endothelial cells.3,4 The corneal epithelium is a stratified, non-keratinized squamous 
layer. It has three types of cells: the most external type of cells are the superficial epithelial cells, in the 
middle are the wing cells located on top of the inner layer which are the basal epithelial cells. Due to its 
histological nature, the epithelium has the primary function of providing a barrier to the cornea and to 
the entire eyeball. Bowman’s layer is composed of thin, type I, III, V and VI collagen microfibrils. It is 
not an independent membrane, but a modification of the most superficial portion of the stroma of the 
cornea. The stroma represents the main support of the corneal structure and comprises up to 90% of its 
volume. This compartment is about 450 µm thick and contains nerves, stromal keratocytes with 
different morphology and type I and V collagen fibers. Dua’s layer is a strong acellular layer in the pre-
Descemet’s cornea, made of 5 to 8 thin lamellae of tightly packed type I, IV, and VI collagen bundles 
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running in longitudinal, transverse, and oblique directions.5 The Descemet’s membrane represents the 
basal membrane of the posterior epithelium. It is formed by very thin filaments of type IV collagen, 
which are arranged in a very regular pattern. The endothelium is a monolayer of cells that aids in 
keeping the corneal transparency not only by its barrier function, but also by its ionic pump function. 
The conjunctiva consists of an epithelium and an underlying loose connective tissue, known as the 
lamina propria; both are separated by the epithelial basement membrane. The epithelial histology is 
stratified non-squamous and consists of two-to-three cell layers having cuboidal morphology in most 
parts. The lamina propria is rich in bone marrow-derived cells that form a mucosal immune system 
known as the conjunctiva-associated lymphoid tissue and of blood vessels of different kinds. Apart 
from capillaries and lymph vessels, specialized high endothelial venules for the regulated migration of 
lymphoid cells are present in the conjunctiva.6 They are a normal component of ocular lymphoid tissue, 
have a characteristic ultrastructure as in other lymphoid tissues, and express cell adhesion molecules. 
The tear film covers the ocular surface, and provides major refractive power of the visual system, 
nutrition, lubrication and protection.7 It forms a thin film layer of 8 µm thick. Although typically 
considered as formed of three layers (namely the external lipid layer, the central aqueous layer and the 
inner mucin layer), it is now recognized that the tear film is more a lipid boundary layer with aqueous 
phases incorporating differing concentrations of mucins throughout. Meibomian and Moll glands 
produce the lipid component, mainly wax esters, triglycerides, free fatty acids, as well as neutral 
diesters. Lachrymal glands produce the aqueous component and goblet cells which are located in the 
conjunctiva, secrets the mucin and contains membrane associated glycoproteins. Other components of 
the tear film are metabolites, proteins and electrolytes. Interestingly, the proteins contained in the tear 
film take part in other processes, for instance, they work as antimicrobials, anti-inflammatories and also 
help in healing processes after trauma, as well as mechanical protection to the surface of the cornea. 
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Figure 1.
Diagrams depicting the Ocular Surface System. (A) Sagittal section through the Ocular Surface
System showing that the ocular surface epithelium is continuous (in pink) with regional
specializations on/in the cornea, conjunctiva, lacrimal and accessory lacrimal glands, and
meibomian gland. Each specialized region of this ocular surface epithelium contributes
components of the tear film (in blue). (B) Frontal view of the Ocular Surface System, which
includes the surface and glandular epithelia of the cornea, conjunctiva, lacrimal gland,
accessory lacrimal glands, and meibomian gland (note enlarged lower lid segment) and their
apical (tears) and basal connective tissue matrices, the eye lashes, those components of the
eyelids responsible for the blink, and the nasolacrimal duct. The functions of the system's
components are integrated or linked by innervation, and the endocrine, vascular and immune
systems. We appreciate the artwork of Peter Mallen in the preparation of this figure.
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Figure 1 - Diagrams depicting the Ocular Surface System from Gipson et al. (A) Sagittal section 
through the Ocular Surface System showing that the ocular surface epithelium is continuous (in pink) 
with regional specializations on/in the cornea, conjunctiva, lacrimal and accessory lacrimal glands, 
and meibomi n gland. Each sp cialized re io of this ocular surface epithelium contributes 
compone ts of the te r film (in blue). (B) Frontal vi w of the Ocular Surface System, which includes 
the surface and glandular epithelia of the cornea, conjunctiva, lacrimal gland, accessory lacrimal 
glands, and meibomian gland (note enlarged lower lid segment) and their apical (tears) and basal 
connective tissue matrices, the eye lashes, those components of the eyelids responsible for the blink, 
and the nasolacrimal duct.  
 
2.2) Ocular surface disease 
Factors disturbing the delicate homeostatic balance of the ocular surface system can adversely affect 
tear film stability and osmolarity, resulting in cellular osmotic, mechanical, and inflammatory damage 
with Dry Eye Disease (DED) onset.8 DED is the most frequent disorder in ocular surface system and in 
Ophthalmological practice in general, with its prevalence ranging from 10.8 % to 57.1 % depending on 
the population analyzed and on the diagnostic criteria used.9-11 
The updated Dry Eye WorkShop (DEWS) definition states that “dry eye is a multifactorial disease of 
the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film 
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instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of 
the tear film and inflammation of the ocular surface”.8 The major classes of DED are aqueous tear-
deficient and evaporative. The first category refers chiefly to a failure of lachrymal gland secretion; the 
latter has been divided to distinguish those causes that are dependent on intrinsic conditions of the lids 
and ocular surface and those that arise from extrinsic influences, for example from environmental, 
occupational and pollution.  
There are a lot of tests performed to diagnose DED and to monitor the efficacy of the related therapy.12 
The main tests are summarized below: 
- Schirmer Test type I is obtained by putting paper strips over the lower lid margin, midway between 
the middle and outer third and by evaluating the measurement of the wet paper after 5 minutes. It is an 
estimation of tear flow production stimulated reflexly by insertion of a filter paper into the conjunctival 
sac. Values higher than 10 sec/5 min are considered normal.  
- Tear Film Break-Up time (TBUT) is defined as the interval in seconds between the last complete blink 
and the first appearance of a dry spot, or disruption in the tear film. It is an index of tear stability. 
Values higher than 10 sec are considered normal. 
- Ocular surface staining is used to show the damaged areas of cornea and conjunctiva where colorants 
can deposit. Usually in the clinical practice fluorescein is used to grade the staining of the cornea while 
lissamine green to grade the staining of the bulbar conjunctiva. Three systems for quantifying staining 
of the ocular surface are currently used, the van Bijsterveld system,13 the Oxford system14 and a 
standardized version of the National Eye Institute/Industry Workshop system.15 
- Tear osmolarity is obtained by the collection of small nanoliter tear sample by a standard 
micropipette, then automatically transferred to a chip surface. A precise readout is obtained in seconds 
after the transfer. Values lower than 290 mOsmol/L are considered normal. 
- Ocular Surface Disease Index (OSDI) is the most used questionnaire about subjective symptoms 
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employed in the clinical practice to assess the efficacy of such treatment or to grade disease severity; it 
consists of 12 questions about 3 major items: visual function (6 questions), ocular symptoms (3), 
environmental triggers (3). It is validated in dry eye population and used as outcome measure in 
randomized clinical trials.16 Scores lower than 12 are considered normal. 
	
2.3) Graft versus-host disease 
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is utilized primarily as a curative 
treatment for both hematological and non-hematological malignancies.17 In the former disease, the 
graft-vs-leukemia or graft-vs-tumor effect mediated by donor-derived T cells helps to eliminate 
malignant cells in the transplant recipient.18 Graft-versus-host disease (GVHD) is a potentially severe 
complication that may develop after allo-HSCT, with its prevalence ranging from 30% to 70% of 
transplanted patients. A recent analysis by the Center for International Blood and Marrow Transplant 
Research of more than 26000 allo-HSCT patients demonstrated that the incidence of GVHD is 
increasing worldwide.19 In allo-HSCT patients, GVHD is the most common cause of non-relapse 
mortality, which refers to mortality not related to the primary malignancy or disease, among patients 
surviving more than two years.20 Chronic GVHD manifests as an autoimmune-like inflammatory 
disease and occurs when donor T cells respond to genetically defined proteins on host cells. The most 
important proteins are Human Leukocyte Antigens (HLA),21 which are highly polymorphic and are 
encoded by the major histocompatibility complex (MHC). Class I HLA (A, B, and C) proteins are 
expressed on almost all nucleated cells of the body at varying densities. Class II proteins (DR, DQ, and 
DP) are primarily expressed on hematopoietic cells (B cells, dendritic cells, monocytes), but their 
expression can be induced on many other cell types following inflammation or injury. Despite HLA 
identity between a patient and donor, approximately 40% of patients receiving HLA-identical grafts 
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develop GVHD due to genetic differences that lie outside the HLA loci, or “minor” histocompatibility 
antigens (HA). Based on an early Seattle experience, acute GVHD was defined to occur prior to day 
100, whereas chronic GVHD occurred after that time.22-24 This definition is far from satisfactory, and 
more recently National Institutes of Health (NIH) classification includes late-onset acute GVHD (after 
day 100) and an overlap syndrome with features of both acute and chronic GVHD.25,26  
Chronic GVHD, the major cause of late non-relapse death following HSCT, may be progressive (active 
or acute GVHD merging into chronic), quiescent (acute GVHD that resolves completely but is later 
followed by chronic GVHD) or it may occur de novo. The best documented risk factors for chronic 
GVHD are a history of acute GVHD (seen in 40%-60% of cGVHD patients), the use of peripheral 
blood stem cells (PBSCs) as source of transplantation, a female donor-male recipient combination, 
older patient age and the use of HLA-mismatched or unrelated donors.26-28 The manifestations of 
chronic GVHD are somewhat protean, and are often of an autoimmune nature. Clinical signs often first 
appear in the buccal mucosa. New consensus criteria for the diagnosis and staging of chronic GVHD 
have recently been developed.26  
 
2.4) GVHD and the eye  
Ocular tissues affected by acute and chronic forms of GVHD include the eyelid and periorbital skin, 
conjunctiva, cornea, lens, lacrimal system, sclera, uvea, and retina. Cataract formation is a common late 
complication of allo-SCT. It is mainly attributed to irradiation and steroid therapy, and is the most 
common cause of visual acuity loss among this type of patients.29,30 Patients receiving total body 
irradiation are at higher risk of developing cataracts than recipients of fractionated total body 
irradiation (83% vs. 21% at 6 years); it tends to develop much earlier in the former group as well. 
Nonetheless, most surviving patients will eventually require cataract surgery. Other ocular 
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manifestations of GVHD include cutaneous complications such as eyelid dermatitis, lagophthalmos and 
ectropion, poliosis, madarosis, and vitiligo.29 Uveitis can occur in up to 8% of cases with chronic 
GVHD, and it is important to distinguish infectious etiologies or neoplastic masquerade syndrome from 
noninfectious uveitis. Neuro-ophthalmologic complications such as disc edema are likely secondary to 
the toxic effects of chemotherapeutic agents such as cyclosporine A and/or coexisting medical 
conditions, and are usually reversible.31 The main vitreoretinal complication seen in association with 
GVHD is retinal microvasculopathy that may occur in 10% of cases. Findings include optic disc 
edema, cotton-wool spots in the fundus, intraretinal and vitreous hemorrhage, and lipid deposits. 
Posterior segment complications also include infections such as infectious retinitis from 
cytomegalovirus (CMV), herpes simplex virus, or varicella zoster virus, central serous 
chorioretinopathy and posterior scleritis.29  
 
2.5) GVHD and the ocular surface 
Throughout the NIH Criteria, diagnostic signs and symptoms refer to those manifestations that 
establish the presence of chronic GVHD without need for further testing or evidence of other organ 
involvement. Distinctive signs and symptoms of chronic GVHD refer to those manifestations that are 
not ordinarily found in acute GVHD but are not considered sufficient in isolation to establish an 
unequivocal diagnosis of chronic GVHD. Additional testing, such as a biopsy documenting histological 
features of chronic GVHD (or at least “likely” chronic GVHD), is needed to establish the diagnosis of 
chronic GVHD. Other features or unclassified manifestations of chronic GVHD define the rare, 
controversial, or nonspecific features of chronic GVHD that cannot be used to establish the diagnosis 
of chronic GVHD. Signs and symptoms found in both chronic and acute GVHD are referred as 
common features.  
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Distinctive manifestations of chronic ocular GVHD include new onset of dry, “gritty,” or painful eyes, 
cicatricial conjunctivitis, keratoconjunctivitis sicca (KCS), and confluent areas of punctate keratopathy. 
Other features include photophobia, periorbital hyperpigmentation, and blepharitis (erythema and 
edema of the eye lids and telangiectasia of lid margin). New ocular sicca documented by low 
Schirmer’s test with a mean value of 5 mm at 5 minutes (preferably with confirmation of normal values 
at an established baseline) or a new onset of KCS by slit lamp examination with mean Schirmer’s test 
values of 6 to 10 mm (preferably with confirmation of normal values at an established baseline) not due 
to other causes is sufficient for the diagnosis of ocular chronic GVHD for the purpose of treatment and 
for clinical trials designed specifically for ocular GVHD, but an additional distinctive feature is 
necessary to establish eligibility for general chronic GVHD trials (Table 1).  
 
Table 1 – Signs and symptoms of chronic ocular GVHD necessary to reach the diagnosis  
Table 1
Signs and Symptoms of chronic GVHD
Organ or Site Diagnostic (Sufﬁcient to
Establish the Diagnosis of
chronic GVHD)
Distinctive* (Seen in chronic
GVHD, but Insufﬁcient Alone
to Establish a Diagnosis)
Other Features or
Unclassiﬁed Entitiesy
Commonz (Seen with
Both Acute and
chronic GVHD)
Skin Poikiloderma
Lichen planuselike
features
Sclerotic features Morphea-
like features
Lichen sclerosuselike
features
Depigmentation
Papulosquamous lesions
Sweat impairment
Ichthyosis
Keratosis pilaris
Hypopigmentation
Hyperpigmentation
Erythema
Maculopapular rash
Pruritus
Nails Dystrophy
Longitudinal ridging,
splitting or brittle features
Onycholysis
Pterygium unguis
Nail loss (usually symmetric,
affects most nails)
Scalp and
body hair
New onset of scarring or
nonscarring scalp
alopecia (after recovery
from chemoradiotherapy)
Loss of body hair
Scaling
Thinning scalp hair, typically
patchy, coarse or dull
(not explained by endocrine
or other causes)
Premature gray hair
Mouth Lichen planuselike changes Xerostomia
Mucoceles
Mucosal atrophy
Ulcers
Pseudomembranes
Gingivitis
Mucositis
Erythema
Pain
Eyes New onset dry, gritty, or
painful eyes
Cicatricial conjunctivitis
KCS
Conﬂuent areas of
punctate keratopathy
Photophobia
Periorbital hyperpigmentation
Blepharitis (erythema of the
eyelids with edema)
Genitalia Lichen planuselike features
Lichen sclerosuselike features
Erosions
Fissures
UlcersFemales Vaginal scarring or clitoral/labial
agglutination
Males Phimosis or urethral/meatus
scarring or stenosis
GI Tract Esophageal web
Strictures or stenosis in the upper
to mid third of the esophagus
Exocrine pancreatic insufﬁciency Anorexia
Nausea
Vomiting
Diarrhea
Weight loss
Failure to thrive (infants
and children
Liver Total bilirubin, alkaline
phosphatase > 2 ! upper
limit of normal
ALT > 2 ! upper limit of
normal
Lung Bronchiolitis obliterans
diagnosed with lung biopsy
BOSx
Air trapping and
bronchiectasis on chest CT
Cryptogenic organizing
pneumonia
Restrictive lung diseasek
Muscles, fascia,
joints
Fasciitis
Joint stiffness or contractures
secondary to fasciitis or sclerosis
Myositis or polymyositis{ Edema
Muscle cramps
Arthralgia or arthritis
Hematopoietic
and Immune
Thrombocytopenia
Eosinophilia
Lymphopenia
Hypo- or hyper-gammaglobulinemia
Autoantibodies (AIHA, ITP)
Raynaud’s phenomenon
Other Pericardial or pleural effusions
Ascites
Peripheral neuropathy
Nephrotic syndrome
Myasthenia gravis
Cardiac conduction abnormality or
cardiomyopathy
ALT indicates alanine aminotransferase; AIHA, autoimmune hemolytic anemia; ITP, idiopathic thrombocytopenic purpura.
* In all cases, infection, drug effect, malignancy, or other causes must be excluded.
y Can be acknowledged as part of the chronic GVHD manifestations if diagnosis is conﬁrmed.
z Common refers to shared features by both acute and chronic GVHD.
x BOS can be diagnostic for lung chronic GVHD only if distinctive sign or symptom present in another organ (see text).
k Pulmonary entities under investigation or unclassiﬁed.
{ Diagnosis of chronic GVHD requires biopsy.
M.H. Jagasia et al. / Biol Blood Marrow Transplant 21 (2015) 389e401 395
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Patients with ocular symptoms before tran pl ntation should be evaluated by an Ophthalmologist for 
assessment of ocular surface abnormalities, including presence of KCS, conjunctival scarring, and 
inflammation. Some Experts strongly encourage baseline evaluation after transplantation 
(approximately day 100).32,33 The scoring of ocular involvement includes the number f ti es a patient 
has to use lubricant eye drops each day. Th  International C nsensus Guidelines on ocular GVHD have 
proposed a more detailed scoring schema, which involves comprehensive ophthalmological evaluation, 
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including pre-transplantation evaluation.33 These remain to be validated and should be considered in 
clinical trials addressing ocular involvement. Schirmer’s test may be useful for diagnosis of ocular 
GVHD, but the numerical values are not useful for follow-up of ocular GVHD due to poor correlation 
with symptom change.34 For this reason, Schirmer’s test values have been removed from the scoring 
form in the current recommendation.  
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EXPERIMENTAL SECTION 
3) Purpose 
Several studies described ocular surface impairment in hematological patients after HSCT, and 
identified risk factors for the development of ocular GVHD.32,35-39 Conversely, limited information is 
available about ocular surface changes after HSCT compared to pre-transplant baseline condition in the 
same subjects.40 
Indeed, a comprehensive baseline ophthalmologic evaluation before HSCT has been recently 
recommended by the First International Chronic Ocular GVHD Consensus Group,33 the German-
Austrian-Swiss Consensus Conference41 and the 2015 updated NIH Consensus Conference,26 with the 
aim to classify the onset of ocular symptoms and signs only after HSCT as incident cases. On the 
contrary, if dry eye disease is already present before HSCT, current criteria to diagnose ocular GVHD 
may be not fulfilled and the diagnosis should not be reached.  
Therefore, the purpose of the present study was to comprehensively evaluate ocular surface parameters 
in the same hematological patients before and after allogeneic hematopoietic stem cell transplantation, 
and to correlate them with clinical and transplant variables. 
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4) Materials and methods 
Patients and transplant procedure 
Data has been prospectively collected over the period March 2007 to March 2014. The study followed 
the tenets of the Declaration of Helsinki, and was approved by the Ethics Committee of the S.Orsola-
Malpighi Teaching Hospital. Informed consent was obtained from all patients when returning for 
subsequent check-ups. In our routine practice, the two scheduled ophthalmological visits are performed 
before HSCT and conditioning regimen (V0) and in a time window ranging from 3 to 6 months after 
HSCT (V1).42 Data from 203 patients undergoing HSCT at the Hematology Institute “L.A. Seragnoli”, 
University of Bologna, S. Orsola-Malpighi Teaching Hospital, in Bologna (Italy) were retrieved. Only 
the 113 charts containing ophthalmological data to be included in the study analysis and collected at V0 
and V1 were further selected. Cases excluded referred to: twenty-eight patients who had not received 
an ophthalmological visit in the first 6 months after HSCT due to poor general health conditions or for 
the occurred death; twenty-five patients whose charts had not been found to be fully completed; thirty-
seven patients living out of our area who had been referred to another eye Center in the post-HSCT 
follow-up. Twenty further cases were excluded for the history of uveitis (n=4), retinitis (n=8), and 
concomitant use of eye drops for the treatment of glaucoma (n=8). 
Ninety-three Caucasian patients fulfilled the criteria and were then finally included in the study. For the 
statistical analysis, patients were divided into two groups according to the underlying disease: chronic 
lymphoproliferative disorders (LPDs) including Hodgkin lymphoma (HL), non-Hodgkin lymphoma 
(NHL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and stem cell malignancies 
(SCMs) including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), 
myelodysplastic syndrome (MDS) and chronic myeloid leukemia (CML). The disease phase at 
transplant was classified as early and advanced. Patients with CML in first chronic phase, ALL and 
AML in the first complete remission and lymphomas in complete remission were considered as early 
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phase; all the remaining cases were considered as advanced phase. Twenty patients (21.5% of the total) 
received HSCT from HLA-identical siblings (Related Donors, RD) and seventy-three (78.5%) from 
voluntary unrelated donors (VUD). Human leukocyte antigen (HLA) matched were defined all the 
pairs 10/10 loci matched; if the matching was less than 10/10 they were classified as mismatch. 
Sources of hematopoietic stem cells were bone marrow (BM) in forty-one cases (44.0%), peripheral 
blood  (PB) in 46 cases (49.5%) and cord blood (CB) in 6 cases (6.5%).  In the analysis, stem cells 
from BM and CB were considered in the same group compared to PB. The intensity of conditioning 
regimen was standard in 64 patients (69% of the total) and reduced-intensity in 29 patients (31%). 
Conditioning regimens were busulfan-based (54 patients) or total body irradiation (TBI, unfractioned, 
800 cGy from Linear Accelerator at low dose rate) -based (10 patients). Reduced intensity regimens 
were Tiothepa 10 mg/kg - Cyclophosphamide 60 mg/kg - Fludarabine 60 mg/sqm (20 patients) or 
Melphalan - Fludarabine (9 patients). All patients received GVHD prophylaxis with Cyclosporin-A and 
short term Methotrexate (days 1,3,6,11, with 15-10-10-10 mg/sm) or Mycophenolate mofetil (15 mg/kg 
bid from day +1 to day +30). In addition, all transplants from unrelated donors received 
antylymphocyte globulin (ATG-F, Grafalon, Bad Homburg, Germany) at 15-30 mg/kg total dose while 
only 11 (55%) patients receiving transplants from their HLA-identical sibling did. Ocular and systemic 
GVHD were diagnosed by the standard NIH criteria, i.e. the ocular involvement is only a distinctive 
manifestation and an additional distinctive feature of another organ is necessary to establish 
diagnosis.25,26 Patients were allocated in single, air-positive pressure rooms with HEPA-filtered air. 
Anti infectious prophylaxis was accomplished with levoxacin and fluconazole during the transplant 
period and acyclovir and cotrimoxazole until the 9th month after transplant. In case of 
Cytomegalovirus (CMV) DNA positivity, CMV pre-emptive therapy was administered using 
gancyclovir or foscarnet if gancyclovir was contraindicated. All patients received filtered and irradiated 
blood products. 
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Ophthalmological examination 
Ophthalmological examinations were always performed before HSCT and conditioning regimen (V0) 
and 3-6 months later (V1), as described elsewhere.42 Briefly, subjective discomfort symptoms were 
graded 0 to 100 with the Ocular Surface Disease Index (OSDI) score. The ophthalmological 
examination was performed from the least to the most invasive test as it follows: tear stability was 
measured by Tear Film Break Up Time (TBUT, average of three measurements) using 2 µL sodium 
fluorescein (Fluoralfa 0.25%, Alfa Intes, Italy); corneal and conjunctival fluorescein stainings were 
assessed under cobalt blue illumination with the aid of a 7503 Boston yellow filter kit (equivalent to 
Kodak Wratten 12) to enhance staining details and graded according to the NEI (National Eye Institute) 
score and van Bijsterveldt score, respectively; tear production was estimated by the 5-minute Schirmer 
test performed with sterile strips without anesthetic (ContaCare Ophthalmics and Diagnostics, Gujarat, 
India).  
Conjunctival injection was graded as previously described as stage I: hyperemia; stage II: hyperemia 
with serosanguinous chemosis; stage III: pseudomembranous conjunctivitis; stage IV: 
membranous/pseudomembranous conjunctivitis plus corneal epithelial sloughing.43 
Meibomian gland dysfunction (MGD) was assessed to grade the quality, expressibility, and volume of 
gland secretion, according to the modified MGD scoring system proposed by Foulks and Bron (range 
0-27).44 
Classification of DE patients was based on a series of thresholds according to the Dry Eye WorkShop 
severity score8 (DEWS, ranging from the less severe grade 1 to the most severe grade 4) and modified 
after Sullivan et al.45 The criteria required evidence of symptoms, with an OSDI score > 5 and in 
addition, at least one eye had to exceed thresholds on two of the five subset signs, chosen from TFBUT 
< 8, Schirmer test ≤ 7, corneal staining > 0, conjunctival staining > 0, and MGD score > 5. The DE 
severity was assigned depending on the highest number of values falling under each grade. Post versus 
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pre HSCT changes were defined as worsening if the increase of at least one point in the level grade 
occurred. 
 
Ocular treatment 
Ocular treatment was prescribed to patients affected by DED already at baseline according to DEWS 
guidelines driven by DED severity score. Briefly, hyaluronic-based tear substitutes, nocturnal ointment 
and lid hygiene were prescribed in mild-moderate cases (DEWS severity grade 1-2) while additional 
anti-inflammatory therapy (steroids – loteprednol etabonate 0.5% ophthalmic suspension [Lotemax, 
Bausch and Lomb,Rochester, NY], 4 times/day for 4 weeks),46 - or cyclosporine - galenic preparation 
(0.1% in oil, 2 times/day)47 was prescribed in most severe cases (DEWS severity grade 3-4).48  The 
same rationale was used in patients developing or worsening DE condition after HSCT.  
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5) Statistical analysis 
Statistical evaluation was performed by using the MedCalc and IBM SPSS ver. 20.0. Data from both 
eyes were collected from charts, but only the value from the worst eye was taken into consideration for 
statistical purposes. All data were expressed as mean ± SD and median (min value; max value) [95% 
confidence interval for the median].  
Pre- and post-HSCT values changes were evaluated by Wilcoxon test for related samples, Mann-
Whitney test for independent samples. For each ocular parameter the post versus pre-HSCT values and 
the differences between post and pre-HSCT values (D) were correlated to pre-HSCT values by 
Spearman Coefficient Correlation (small correlation strength 0.10 to 0.29; medium 0.30 to 0.49; large 
0.50 to 1.00). Univariate (Chi-square test, Odds Ratio) and multivariate logistic forward regression 
analysis were used to assess the association between demographic, ocular, hematological and transplant 
related variables and DE post HSCT. Risk for DE was also estimated by odds ratio (OR) with 95% 
confidence intervals that independently associated the disease. Data were considered to be statistically 
significant if p<0.05. 
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6) Results  
Demographic, hematological and ophthalmological data were summarized in Table 2. The median 
interval between HSCT and V1 visit was 115 days (97-150) [95-176] (median, 95% CI, min-max 
value). Patients showed a similar distribution between genders, with a not statistically significant 
difference between males and females. Stratification by gender is important because the prevalence of 
DE is significantly higher in females.49 
 
Table 2 – Clinical and demographic features of subjects included in the study. Data are expressed as median (min-max 
values) [95% CI]. 
 
 Patients number % vs total  
DEMOGRAPHIC DATA   
Females  48 51.5 
Males  45 48.5 
Age (yrs) 46 (18-64) [43-48]  
HAEMATOLOGICAL HISTORY   
Disorders   
AML 28 30.0 
ALL 19 20.5 
HL 9 9.5 
CML 9 9.5 
NHL 9 9.5 
MM 8 8.5 
MDS 7 7.5 
CLL 4 5.0 
Time from diagnosis to HSCT (days) 281 (113-2783) [231-464]  
Disease stage    
Early  34 36.5 
Advanced  59 63.5 
Previous autograft 9 9.6 
Previous chemotherapy  
medications (no. cycles) 
  
< 3 cycles 40 43.0 
>3 cycles 53 57.0 
OCULAR HISTORY   
Contact Lens wearers 17 18.5 
VDT users 12* 13.0 
Previous ocular surgery 7 7.5 
HSCT PARAMETER   
Donor characteristics   
Age (yrs) 32 (19-68) [28-33]  
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VUD  73 78.5 
HLA match 26 28 
HLA mismatch 47 50.5 
RD  20 21.5 
Sex mismatch 45 48 
Conditioning regimen   
Reduced 29 31 
Myeloablative 
 
 
 
 
64 69 
Stem Cell Source   
Bone marrow 41 44 
Peripheral blood 46 49.5 
Cord blood 6 6.5 	
Abbreviations: VDT = Video terminal users; ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; HL = 
Hodgkin lymphoma; CML = chronic myeloid leukemia; NHL = non-Hodgkin lymphoma; MM = multiple myeloma; MDS 
= myelodysplastic syndrome; CLL = chronic lymphocytic leukemia; VUD = Voluntary Unrelated Donors; RD = Related 
Donors 
 
 
 
Pre-HSCT ophthalmologic parameters analysis   
Forty-three patients (47%) were classified as non-DE subjects whereas fifty patients (53%) were 
classified as DE sufferers.  Of these, 25 patients were classified as DEWS modified score 1 (50% of the 
total DE-subjects), 21 patients as score 2 (42% of the total) and 4 patients as score 3 (8% of the total) 
(Figure 2). Results of ophthalmological parameters for both non-DE (white rows) and DE patients 
(grey rows) were summarized in the left column of Table 3. The DE patients appeared to be moderately 
symptomatic according to OSDI, with a normal tear production as median and a hyper evaporative DE 
type with tear instability and pathological MGD scores. 
Hyaluronic-based tear substitutes, nocturnal ointment and lid hygiene were prescribed to 46 patients 
(DEWS severity levels 1-2) while loteprednol etabonate 0.5% ophthalmic suspension was prescribed to 
the four most severe patients (DEWS severity level 3). 
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Post-HSCT parameters analysis 
DE disease was present at the V1 visit in 72 patients (77% of the total): 31 patients (33%) were 
classified as DEWS severity level 1, 32 patients (34.5%) as DEWS level 2 and 7 patients (9.5%) as 
DEWS level 3 (Fig. 2).  
After HSCT, a statistically significant worsening of ocular parameters compared to pre-transplant 
values was shown for both groups.  Only conjunctival surface damage did not worsen in DE patients 
after HSCT, remaining comparable to values pre transplant. Despite the significant reduction, the 
Schirmer test as a median after HSCT resulted in the normal range, whereas the TFBUT as a median 
was found in the pathological range.  
Among the post HSCT DE patients, 22 out of 43 non-DE pre HSCT subjects developed DE after: these 
incident cases showed different DEWS levels of severity as shown in Fig 2.  
 
 
Fig. 2 –Distribution of dry eye disease in patients before and after HSCT. The distribution is shown for the whole 
population (ALL) in the upper part, for patients who had not been diagnosed as DE pre-HSCT (no-DE) in the middle part, 
and for patients who had been diagnosed as DE pre-HSCT (DE) in the lower part. Abbreviation: DE= Dry Eye 
 
Also these DE patients could be classified as hyper evaporative DE type (mean values ± SD: Schirmer 
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test 20.4±12.5 mm/5’; TFBUT 6.3±2.1 sec; MGD score 7.5±4.5).  Results of ophthalmological 
parameters for non-DE (white rows) and DE patients (grey rows) were summarized in the right column 
of Table 3. Post HSCT ophthalmological parameters from these two groups of patients were compared; 
a statistically significant difference was found with worst values shown in the DE pre HSCT group of 
patients (p always <0.001). 
 
Table 3 - Results from ophthalmological examinations in DE patients before and after HSCT. Values are expressed as mean 
±SD and median (minimum value – maximum value) [95% Confidence Interval]. 
White rows - Results for the group of subjects not diagnosed as suffering from DE before HSCT 
Grey rows - Results for the group of subjects diagnosed as suffering from DE before HSCT 
 
 
 
        
 
OSDI score 
9.7±11.7 
6 (6-59) [6-8] 
18.2±17.1 
15 (6-73) [12-20] 
<0.0001 
TFBUT (seconds) 
6.8±2.3 
7.5 (1-15) [7-8] 
6.0±2.1 
6.1 (1-12) [5-7] 
<0.01 
Schirmer test (mm length/5’) 
17.5±13.2 
15 (9-40) [10-20] 
15.2±11.2 
10 (1-25) [0-12] <0.01 
Conjunctival staining (van 
Bijsterveldt score) 
2.1±2.5 
3 (0-9) [0-3] 
3.6±3.1 
3 (0-9) [0-3] 
0.4 
Corneal damage (NEI  staining 
score ) 
1.9±2.0 
2 (0-12) [1-2] 
2.1±2.4 
2 (0-12) [2-4] 
<0.01 
MGD score 
6.5±3.5 
7 (3-10) [5-8] 
9.1±7.5 
9.5 (5-16) [8-13] 
<0.01 
Conjunctival injection 
0.5±0.5 
0.6 (0-1) [0-1] 
0.9±0.8 
0.9 (0-2) [0-2] 
<0.01 
Abbreviations: OSDI = Ocular Surface Disease Index; TFBUT = Tear Film Break-Up Time; NEI = National Eye Institute; 
MGD = Meibomian Gland Dysfunction. 
Parameters Pre-HSCT Post-HSCT p 
OSDI score 
 
6.4±7.4 
4 (0-15) [2-6] 
15.2±14.7 
13 (2-56) [7-19] 
<0.0001 
TFBUT (sec) 
 
13.1±3.0 
15 (4-15) [12-15] 
9.2±4.6 
8 (1-15) [8-12] <0.0001 
Schirmer test (mm length/5’) 
30.1±12.1 
40 (10-40) [30-40] 
23.3±12.2 
20 (2-40) [16-27] 
<0.001 
Conjunctival staining (van 
Bijsterveldt score) 
1.15±1.74 
0 (0-5) [0-1] 
2.21±2.23 
2 (0-8) [1-2] 
<0.01 
Corneal damage (NEI  score) 
0±0 
0 (0-0) [0-0] 
1.7±2.1 
0 (0-6) [0-3] 
<0.0001 
MGD score 
1.5±1.1 
2.5 (1-4) [2-3] 
6.5±5.5 
7.5 (4-14) [7-12] 
<0.0001 
Conjunctival injection 
0.2±0.2 
0.4 (0-1) [0-1] 
0.7±0.8 
0.8 (0-2) [0-2] 
<0.01 
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Thirty-four out of fifty DE pre HSCT patients did not change severity grade whereas the remaining 16 
worsened their pre-HSCT DEWS severity level, mostly shifting from level 1 to level 2. The DE profile 
did not change after the transplant from hyper evaporative to aqueous deficiency or vice versa. 
Hyaluronic-based tear substitutes, nocturnal ointment and lid hygiene were prescribed to sixty-five 
patients (DEWS severity levels 1-2) while loteprednol etabonate 0.5% ophthalmic suspension was 
prescribed to the seven most severe patients (DEWS severity level 3). 
Systemic chronic GVHD was diagnosed in 39 patients (42% of the total) while ocular GVHD in 33 
patients (35.5% of the total) regardless the presence of DE pre HSCT, according to NIH Criteria. 
Conversely, the cases of ocular GVHD decreased to 11 cases (12%) in our population when taking into 
account only incident cases. Also ocular GVHD patients could be classified as hyper evaporative DE 
type.    
 
 
Correlations 
A statistically significant correlation between post versus pre transplant values was only found for 
Schirmer test (rho=0.512) and OSDI score (rho=0.461). The difference between pre and post-HSCT 
values (Δ) was calculated and correlated to the corresponding pre-HSCT value. Δ values of all ocular 
parameters showed a significant inverse correlation with pre-HSCT values:  TFBUT (rho= -0.577), 
Schirmer test (rho= -0.605), OSDI (rho= -0.364), NEI score (rho= -0.525) and van Bijsterveldt score 
(rho= -0.534) (always p<0.001). This finding indicates a greater worsening after HSCT in patients who 
had already shown impaired parameters before HSCT.  
 
Univariate analysis  
In univariate analysis, increasing recipient age, recipient female sex and higher CD34+ cells infused 
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were associated with a significant higher incidence of DE after HSCT in those subjects not suffering 
from DE before HSCT (Table 4 A). Advanced disease stage at the time of HSCT, donor-recipient sex 
mismatch (males receiving from females), related donors, and peripheral blood cells as stem cell source 
were associated with a significant higher incidence of DE after HSCT in subjects either having or not 
having DE before HSCT (Table 4 A and B).  
 
Table 4A - Univariate odds ratios (OR) for developing DE after HSCT in the subgroup of patients defined as not suffering 
from DE before HSCT. 
 
VARIABLE UNADJUSTED OR 
(95% CI) 
P  
    
Recipient age (years) § 1.04 (1.01-1.08) 0.03  
Recipient gender (Female vs Male) §  1.43 (1.20-4.43) 0.01  
    
Ocular variables    
VDT use 0.27 (0.10-1.11) 0.21  
Previous eye surgery 0.21 (0.48-1.23) 0.32  
    
Hematological variables    
Type of disease 0.57 (0.16-2.06) 0.39  
Time from diagnosis to HSCT (> 6 
months) 
0.81 (0.28-2.34) 0.71  
Advanced disease stage§ 1.23 (1.08-3.55) 0.02  
Previous chemotherapy medications 
(no. cycles) 
1.06 (0.87-1.30) 0.50  
    
Transplant variables    
Donor-recipent sex mismatch§  1.33 (1.12-4.47) 0.03  
Donor age  1.07 (0.98-1.16) 0.07  
Donor type (related donors) § 7.50 (1.56-35.9) 0.03  
Stem cell source (PB cells) § 2.12 (1.49-5.02) 0.01  
Intensity of conditioning regimen 0.71 (0.29-1.74) 0.45  
HLA mismatch 0.43 (0.10-1.76) 0.24  
CD34+ cells infused § 1.11 (1.09-1.92) 0.01  
    
GVHD systemic ° 1.23 (1.13-5.38) 0.01  
    
 
§= factors which showed a positive association in predicting DE post HSCT in those patients without DE pre HSCT. 
°= factor positively associated to DE development post HSCT in those patients without DE pre HSCT. 
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Table 4B - Univariate odds ratios (OR) for worsening DE after HSCT in the subgroup of patients defined as those suffering 
from DE before HSCT and worsening DE after HSCT. 
 
 
VARIABLE UNADJUSTED OR 
(95% CI) 
P 
   
Recipient age (years)  0.98 (0.93-1.03) 0.61 
Recipient gender (Female vs Male)  0.98 (0.29-3.26) 0.92 
   
Ocular variables   
CL wear 0.69 (0.21-2.24) 0.53 
VDT use 0.25 (0.15-1.08) 0.28 
Previous eye surgery 0.31 (0.18-1.23) 0.38 
   
Hematological variables   
Type of disease 0.87 (0.22-3.40) 0.84 
Time from diagnosis to HSCT (> 6 
months) 
0.90 (0.36-2.24) 0.83 
Advanced disease stage 1.08 (1.02-4.71) 0.03 
Previous chemotherapy medications 
(no. cycles) 
0.94 (0.79-1.13) 0.55 
   
Transplant variables   
Donor-recipent sex mismatch§  1.17 (1.11-1.61) 0.02 
Donor age  1.02 (0.97-1.09) 0.30 
Donor type (related donors) § 1.22 (1.05-2.42) 0.02 
Stem cell source (PB cells) §  1.31 (1.21-1.89) 0.01 
Intensity of conditioning regimen 0.80 (0.30-2.07) 0.55 
HLA mismatch 1.26 (0.31-5.19) 0.74 
CD34+ cells infused § 1.03 (0.99-1.04) 0.76 
   
GVHD systemic ° 1.51 (1.23-3.53) 0.03 
   
 
§= factors which showed a positive association in predicting worst DE post HSCT in those patients with preexisting DE pre 
HSCT. 
°= factor positively associated to DE worsening post HSCT in those patients with DE pre HSCT. 
 
 
 
Multivariate analysis  
Multiple analysis of variables significant in the univariate, or clinically relevant, did not show any 
statistically significant p value in subjects either having or not having DE before HSCT.  
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7) Discussion 
In this retrospective study data from comprehensive ocular surface evaluation in the same patients 
before and after allogeneic hematopoietic stem cell transplantation were analyzed. To our knowledge, 
only another study was performed on 53 patients analyzing prospectively the same population before 
and after HSCT.40 The remaining studies analyzed ocular surface involvement only after HSCT without 
a baseline examination.32,35-39,50,51 
In our study DE was present in 50 patients (53%) before HSCT, this value being higher as compared to 
Ogawa et al40 who reported an incidence of 17%, and at the upper limit of the wide range (5-50%) 
reported for a general hospital-based population.52-57  
The explanation could likely to be related to the history of the patients population of this study, who 
underwent several previous chemotherapy and total body irradiation treatments before allo-HSCT. 
However, a similar prevalence was shown in a previous study from our group, where a larger 
population of pre-transplant patients had been analyzed.42 However no specific previous treatments had 
been found to be related to DE pre-HSCT. The DE patients showed mild to moderate levels of severity 
in both signs and symptoms with a hyper evaporative DE profile. To the best of our knowledge, pre 
HSCT dry eye profile had not been characterized previously. 
After HSCT, 72 patients (77%) were found to be affected by DE, mostly presenting tear instability and 
pathological MGD score whereas the value of tear secretion as a median was found in the normal 
range. It is difficult to compare our results with the several previous reports in the literature only 
dealing with DE in post HSCT, and this is due to different time interval from HSCT and 
ophthalmological examination, concurrent systemic therapy, underlying hematological malignancies 
(not always specified), heterogeneous criteria for DE diagnosis. However, the ocular surface 
parameters shown after HSCT in our patients were similar to those found in mild DE populations from 
another study.58 In addition, MGD functional impairment found in our study is in agreement with 
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others 59 who found meibomian gland morphological alterations and loss after HSCT.  
Twenty-two out of the seventy-two DE patients after HSCT were classified as incident cases, i.e. those 
not diagnosed as DE before HSCT. These patients also showed a mild to moderate hyper evaporative 
profile.  
The influence of ocular, hematological and HSCT-related variables on the ocular GVHD or DE 
development post-HSCT was investigated previously. The heterogeneity of populations studied and 
their treatment along with the not univocal classification for GVHD (in particular those preceding the 
NIH guidelines) in the previous literature make results difficult to be compared. In addition, to date 
only one study analyzed the same patients before and after HSCT, providing data both from subjects 
not having a DE pre-HSCT and developing a DE post-HSCT and from those worsening a DE pre-
HSCT.40 
Several factors as donor-recipient sex mismatch, increasing recipient age and peripheral blood as stem 
cell source had been identified as associated factors either for ocular and systemic GVHD.32,39,40,50,60 
On the contrary, the role of the conditioning regimen, donor-recipient relation and HLA compatibility 
is still unclear.32,35,40,50,51  
In the present study, increasing recipient age and chronic systemic GVHD were confirmed as 
associated with DE post-HSCT 39,40,50. Recipient female gender, PBSC as stem cell source, related 
donors, donor-recipient sex mismatch were found to be associated with DE onset post-HSCT, despite 
previous conflicting results from previous ophthalmological studies.32,36,39,40,50  
However, some of these (increasing recipient age, PBSC as stem cell source, donor-recipient sex 
mismatch) are widely recognized as associated factors with GVHD onset in the hematological 
literature.60  
Some unexpected results were found for the analysis of conditioning intensity and related donors as 
associated factors. The intensity of conditioning regimen was not associated with an increased risk of 
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DE post-HSCT, in disagreement with the hematological literature,60 but the great variability in 
protocols and treatment regimen used could have affected more reliable correlations. 
Related donors showed a significant association with DE post-HSCT, in agreement with some 
Authors35 but not with others.32,36,40,60 This finding could be attributed to the different GVHD 
prophylaxis given according to donor type: all unrelated transplant received antylymphocyte globulin 
in addition to standard prophylaxis (Calcineurin-inhibitor + short term Methotrexate) whereas only 
roughly half patients received ATG in the HLA identical sibling setting. As recently reported ATG 
reduces the incidence and severity of cGVHD after allogeneic transplant from HLA identical sibling 
peripheral blood stem cells; in particular, ocular GVHD appear to be dramatically reduced on the arm 
with ATG.61 
We have also analyzed potential risk factors not previously evaluated in the ophthalmological 
literature; of these, time interval from diagnosis to HSCT and donor age were not found associated with 
DE post HSCT whereas advanced stages of hematological malignancy and the number of stem cells 
infused were found associated to DE post HSCT.    
In our series, the severity of post-HSCT ocular surface impairment was not as high as reported by other 
Authors.32,35-39 No severe corneal complication occurred unlike results from Tabbara et al. in which 
half GVHD patients suffered from corneal ulcers.62 Concordantly, no patient developed DE post-HSCT 
so severe to be classified as DEWS worst severity score 4. A possible explanation is that an ocular 
therapy had been administered to all those patients diagnosed as DE before HSCT, already before 
starting the conditioning regimen, and this could have tempered a DE progression post transplant.  This 
hypothesis appears in agreement with Others who suggested the effectiveness of pre-HSCT initiation of 
therapy before HSCT for the treatment and prophylaxis of DE after transplantation.63 
According to NIH GVHD criteria, ocular GVHD is diagnosed in the event of a new onset of dry, gritty, 
painful eyes, cicatricial conjunctivitis, keratoconjunctivitis sicca or confluent areas of punctate 
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keratopathy observed after HSCT. Ocular involvement represents a distinctive sign and therefore not 
considered to be sufficient as alone to establish an unequivocal diagnosis for general chronic GVHD 
trials.26 Following these guidelines, systemic chronic GVHD was diagnosed in 42% of our patients as a 
whole whereas ocular chronic GVHD in 35.5%, regardless the pre-HSCT ocular impairment. As a 
matter of fact, if a patient already suffers from DE disease before HSCT, ocular surface impairment 
evaluated at the post-HSCT check-up cannot be considered as “incident cases” and cannot be 
diagnosed as post HSCT ocular GVHD. This finding influenced the real prevalence of ocular GVHD 
post HSCT, which decreased in the present study to 12%.  
As already reported, a poor diagnostic performance in diagnosing DE already before HSCT was found 
for the Schirmer Test, which has been recently removed in the NIH Guidelines from the markers of 
severity and from the response criteria.26,64 In addition, as the Schirmer score does not reflect changes 
in ocular GVHD activity, it was not recommended for the measurement of the changes in ocular 
GVHD studies by the Chronic GVHD Consortium.65 
We recognize that in our study further variables potentially influencing the onset and development of 
ocular GVHD were lacking as not found in our medical charts. This limitation occurs in any 
retrospective study based on chart reviews, however this is a major initial study generating data to be 
verified further by larger cohort prospective studies. 
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8) Conclusion 
This study confirmed that DE is present in high percentages in hematological patients undergoing 
hematopoietic stem cell transplantation already before HSCT, as already recently demonstrated by our 
group. This finding demonstrates that comprehensive pre-transplant assessment of ocular surface 
should be highly recommended, as it has been already recognized for functional respiratory values in 
lung GVHD.26,64 This recommendation is not only addressed to an accurate early diagnosis but also to a 
prompt treatment of patients already suffering from dry eye disease, with positive influences in terms 
of lower prevalence and severity of ocular GVHD after HSCT compared to traditional ongoing 
protocols. 
However, further larger prospective multicenter studies based on pre and post-transplantation 
ophthalmic evaluation are needed to identify overall associated factors and the real prevalence of ocular 
GVHD after HSCT that could be overestimated.   
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